Advertisement

The Clinical Impact of Cross-Sectional Imaging on Crohn’s Disease Management

  • Ellen M. ZimmermannEmail author
Chapter

Abstract

A new era of Crohn’s disease management exists where decisions are made by objective data as a necessary adjunct to patient symptoms. Cross-sectional imaging, particularly CT enterography (CTE) and MR enterography (MRE), provides powerful objective insights into the disease process resulting in a firm place for cross-sectional imaging in our current diagnostic and management paradigms. The high sensitivity and specificity of the techniques for the presence of bowel inflammation have helped pinpoint the location and severity of disease enabling diagnosis and facilitating assessment of symptoms. The ability to identify disease complications has helped direct medical therapy and enables more robust presurgical assessment. Emerging data suggest that cross-sectional imaging findings are sensitive to changes in inflammation resulting from our potent biologic therapies and may be used in amazing new ways such as in predicting disease course. Technological advances in CT and MR enterography have provided new insights into the disease processes while enhancing patient safety and tolerability. The goal of this chapter is to provide a gastroenterologist’s view of how cross-sectional imaging fits our current and future management algorithm. These remarkable technologies enable gastroenterologists and radiologists, working together, to serve our patient population in profound ways.

Keywords

Crohn’s disease Ulcerative colitis Inflammation Imaging Fibrosis 

References

  1. 1.
    Ananthakrishan AN, Xavier RJ, Podolsky DK. Inflammatory bowel disease: pathogenesis. In: Podolsky DK, et al., editors. Yamada’s textbook of gastroenterology. 6th ed. New York: Wiley; 2016. p. 1364–77.Google Scholar
  2. 2.
    Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389:1741–55.CrossRefGoogle Scholar
  3. 3.
    Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–94.CrossRefGoogle Scholar
  4. 4.
    Latella R, Sferra R, Speca S, Vetuschi A, Gaudio E. Can we prevent, reduce or reverse intestinal fibrosis in IBD? Eur Rev Med Pharmacol Sci. 2013;17:1283–304.PubMedGoogle Scholar
  5. 5.
    Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–17.CrossRefGoogle Scholar
  6. 6.
    Li Q, Lee CH, Peters LA, Mastropaolo LA, Thoeni C, Elkadri A, Schwerd T, Zhu J, Zhang B, Zhao Y, Hao K, Dinarzo A, Hoffman G, Kidd BA, Murchie R, Al Adham Z, Guo C, Kotlarz D, Cutz E, Walters TD, Shouval DS, Curran M, Dobrin R, Brodmerkel C, Snapper SB, Klein C, Brumell JH, Hu M, Nanan R, Snanter-Nanan B, Wong M, Le Deist F, Haddad E, Roifman CM, Deslandres C, Griffiths AM, Gaskin KJ, Uhlig HH, Schadt EE, Muise AM. Variants in TRIM22 that affect NOD2 Signaling are associated with very-early-onset inflammatory bowel disease. Gastroenterology. 2016;150:1196–207.CrossRefGoogle Scholar
  7. 7.
    Al Nabhani Z, Dietrich G, Hugot JP, Barreau F. Nod2: the intestinal gate keeper. PLoS Pathog. 2017;13:e1006177.  https://doi.org/10.1371/journal.ppat.1006177.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    de Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:739–49.CrossRefGoogle Scholar
  9. 9.
    Isene R, Bernklev T, Høie O, Munkholm P, Tsianos E, Stockbrügger R, Odes S, Palm O, Småstuen M, Moum B, The Ec-Ibd Study Group. Extraintestinal manifestations in Crohn’s disease and ulcerative colitis: results from a prospective, population-based European inception cohort. Scand J Gastroenterol. 2015;50:300–5.CrossRefGoogle Scholar
  10. 10.
    Ministro P, Martins D. Fecal biomarkers in inflammatory bowel disease: how, when and why? Expert Rev Gastroenterol Hepatol. 2017;11:317–28.CrossRefGoogle Scholar
  11. 11.
    Bruining DH, Bhatnagar G, Rimola J, Taylor S, Zimmermann EM, Fletcher JG. CT and MR imaging in Crohn’s disease: current and future applications. Abdom Imaging. 2015;40:965–74.CrossRefGoogle Scholar
  12. 12.
    Colombel JF, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology. 2017;152:351–61.CrossRefGoogle Scholar
  13. 13.
    Enns RA, Hookey L, Armstrong D, Bernstein CN, Heitman SJ, Teshima C, Leontiadis GI, Tse F, Sadowski D. Clinical practice guidelines for the use of video capsule endoscopy. Gastroenterology. 2017;152:497–514.CrossRefGoogle Scholar
  14. 14.
    Kopylov U, Ben-Horin S, Seidman EG, Eliakim R. Video capsule endoscopy of the small bowel for monitoring of Crohn's disease. Inflamm Bowel Dis. 2015;21:2726–35.CrossRefGoogle Scholar
  15. 15.
    Quaia E, Gennari AG, Cova MA, van Beek EJR. Differentiation of inflammatory from fibrotic ileal strictures among patients with Crohn's disease based on visual analysis: feasibility study combining conventional B-mode ultrasound, contrast-enhanced ultrasound and strain elastography. Ultrasound Med Biol. 2018;44:762–70.CrossRefGoogle Scholar
  16. 16.
    Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, et al. Surgery in a population-based cohort of Crohn’s disease from Olmsted County, Minnesota (1970–2004). Am J Gastroenterol. 2012;107:1693–701.CrossRefGoogle Scholar
  17. 17.
    Bosch OG, Ordâs I, Rodriguez S, et al. Comparison of the impact of MRI and colonoscopy on management of Crohn’s disease. Gastroenterology. 2012;142:S-21–2.CrossRefGoogle Scholar
  18. 18.
    Pariente B, Mary JY, Danese S, et al. Development of the Lémann index to assess digestive tract damage in patients with Crohn’s disease. Gastroenterology. 2015;148:52–63.CrossRefGoogle Scholar
  19. 19.
    Schreyer AG, Hoffstetter P, Daneschnejad M, Jung EM, Pawlik M, Friedrich C, Fellner C, Strauch U, Klebl F, Herfarth H, Zorger N. Comparison of conventional abdominal CT with MR-enterography in patients with active Crohn’s disease and acute abdominal pain. Acad Radiol. 2010;17:352–7.CrossRefGoogle Scholar
  20. 20.
    Rimola J, Planell N, Rodríguez S, Delgado S, Ordás I, Ramírez-Morros A, et al. Characterization of inflammation and fibrosis in Crohn’s disease lesions by magnetic resonance imaging. Am J Gastroenterol. 2015;110:432–40.CrossRefGoogle Scholar
  21. 21.
    Adler J, Punglia D, Dillman JR, Polydorides AD, Dave M, Al-Hawary MM, Platt JF, McKenna GJ, Zimmermann EM. CT enterography findings correlate with tissue inflammation in resected small bowel Crohn’s disease. Inflamm Bowel Dis. 2012;18:849–56.CrossRefGoogle Scholar
  22. 22.
    Wagner M, Ko HM, Chatterji M, Besa C, Torres J, Zhang X, Panchal H, Hectors S, Cho J, Colombel JF, Harpaz N, Taouli B. Magnetic resonance imaging predicts histopathologic composition of ileal Crohn’s disease. J Crohns Colitis. 2018;12(6):718–29.CrossRefGoogle Scholar
  23. 23.
    Bruining DH, Zimmermann EM, Loftus EV, Sanborn WJ, Sauer CG, Strong SA. Consensus guidelines for evaluation, interpretation and utilization of CT and MR enterography in small bowel Crohn’s disease patients. Radiology. 2018;286(3):776–99.CrossRefGoogle Scholar
  24. 24.
    Flint A, Chaudhry NA, Riverso M, Pham, A, Moser PP, Mramba LK, Zimmermann EM, Grajo JR. Effective communication of cross-sectional imaging findings in Crohn’s disease: comparing conventional EMR reporting to a published scoring system. Abdom Radiol. 2017.  https://doi.org/10.1007/s00261-017-1368-0.CrossRefGoogle Scholar
  25. 25.
    Chaudhry NA, Riverso M, Grajo JR, Moser PP, Zou F, Homsi M, Punglia DR, Zimmermann EM. A fixed stricture on routine cross sectional imaging predicts disease-related complications and adverse outcomes in patients with Crohn’s disease. Inflamm Bowel Dis. 2017;23:641–9.CrossRefGoogle Scholar
  26. 26.
    Castiglione F, Mainenti P, Testa A, Imperatore N, De Palma GD, Maurea S, Rea M, Nardone OM, Sanges M, Caporaso N, Rispo A. Cross-sectional evaluation of transmural healing in patients with Crohn’s disease on maintenance treatment with anti-TNF alpha agents. Dig Liver Dis. 2017;49:484–9.CrossRefGoogle Scholar
  27. 27.
    Fiorino G, Peyrin-Biroulet L, Bonifacio C, et al. MRE and colonoscopy findings in early Crohn’s disease predict the course of the disease: a prospective observational cohort study. Gastroenterology. 2013;144:S-639.CrossRefGoogle Scholar
  28. 28.
    Bickelhaupt S, Pazahr S, Chuck N, Blume I, Froehlich JM, Cattin R, Raible S, Bouquet H, Bill U, Rogler G, Frei P, Boss A, Patak MA. Crohn’s disease: small bowel motility impairment correlates with inflammatory-related markers C-reactive protein and calprotectin. Neurogastroenterol Motil. 2013;25:467–73.CrossRefGoogle Scholar
  29. 29.
    Li XH, Mao R, Huang SY, Sun CH, Cao QH, Fang ZN, Zhang ZW, Huang L, Lin JJ, Chen YJ, Rimola J, Rieder F, Chen MH, Feng ST, Li ZP. Characterization of degree of intestinal fibrosis in patients with Crohn disease by using magnetization transfer MR imaging. Radiology. 2018;287:494–503.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of GastroenterologyUniversity of FloridaGainesvilleUSA

Personalised recommendations